236 related articles for article (PubMed ID: 36376293)
1. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation.
Shi C; Wang Y; Wu M; Chen Y; Liu F; Shen Z; Wang Y; Xie S; Shen Y; Sang L; Zhang Z; Gao Z; Yang L; Qu L; Yang Z; He X; Guo Y; Pan C; Che J; Ju H; Liu J; Cai Z; Yan Q; Yu L; Wang L; Dong X; Xu P; Shao J; Liu Y; Li X; Wang W; Zhou R; Zhou T; Lin A
Nat Commun; 2022 Nov; 13(1):6951. PubMed ID: 36376293
[TBL] [Abstract][Full Text] [Related]
2. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
[TBL] [Abstract][Full Text] [Related]
3. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Wu Y; Zhang C; Liu X; He Z; Shan B; Zeng Q; Zhao Q; Zhu H; Liao H; Cen X; Xu X; Zhang M; Hou T; Wang Z; Yan H; Yang S; Sun Y; Chen Y; Wu R; Xie T; Chen W; Najafov A; Ying S; Xia H
Nat Commun; 2021 Apr; 12(1):2346. PubMed ID: 33879767
[TBL] [Abstract][Full Text] [Related]
4. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer.
Liu J; Wei L; Hu N; Wang D; Ni J; Zhang S; Liu H; Lv T; Yin J; Ye M; Song Y
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104103
[TBL] [Abstract][Full Text] [Related]
5. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
6. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
[TBL] [Abstract][Full Text] [Related]
7. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
8. A novel SNP in HUWE1 promoter confers increased risk of NOA by affecting the RA/RARα pathway in Chinese individuals.
Shan X; Zhang X; Huang G; Lv J; Ye Z; Jiang C; Jiang X; Cheng J; Lin H; Jiang H; Yue H; Wang Z; Xu W
Andrology; 2024 Feb; 12(2):338-348. PubMed ID: 37290064
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.
Kim SB; Hwang S; Cha JY; Lee HJ
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474186
[TBL] [Abstract][Full Text] [Related]
10. The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy.
Hou B; Chen T; Zhang H; Li J; Wang P; Shang G
Front Immunol; 2023; 14():1123244. PubMed ID: 36733484
[TBL] [Abstract][Full Text] [Related]
11. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.
Hsu JM; Li CW; Lai YJ; Hung MC
Cancer Res; 2018 Nov; 78(22):6349-6353. PubMed ID: 30442814
[TBL] [Abstract][Full Text] [Related]
12. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination.
Yu X; Li W; Liu H; Wang X; Coarfa C; Cheng C; Yu X; Zeng Z; Cao Y; Young KH; Li Y
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719382
[TBL] [Abstract][Full Text] [Related]
14. ATG101 Degradation by HUWE1-Mediated Ubiquitination Impairs Autophagy and Reduces Survival in Cancer Cells.
Lee J; Kim J; Shin J; Kang Y; Choi J; Cheong H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502089
[TBL] [Abstract][Full Text] [Related]
15. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
[TBL] [Abstract][Full Text] [Related]
16. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.
Feng C; Zhang L; Chang X; Qin D; Zhang T
Front Immunol; 2023; 14():1230135. PubMed ID: 37554324
[TBL] [Abstract][Full Text] [Related]
17. NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells.
Zhong B; Zheng J; Wen H; Liao X; Chen X; Rao Y; Yuan P
Genes Genomics; 2022 Sep; 44(9):1071-1079. PubMed ID: 35353342
[TBL] [Abstract][Full Text] [Related]
18. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target.
Zhou J; Ma X; He X; Chen B; Yuan J; Jin Z; Li L; Wang Z; Xiao Q; Cai Y; Zou Y; Cong YS
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215732120. PubMed ID: 36893266
[TBL] [Abstract][Full Text] [Related]
20. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
